Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) was the recipient of a large decrease in short interest in August. As of August 15th, there was short interest totaling 52,200 shares, a decrease of 25.3% from the July 31st total of 69,900 shares. Based on an average trading volume of 199,500 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 199,500 shares, the short-interest ratio is presently 0.3 days.
Shionogi & Co., Ltd. Unsponsored ADR Stock Down 1.1%
Shares of OTCMKTS:SGIOY traded down $0.10 during trading on Friday, hitting $8.95. The stock had a trading volume of 50,649 shares, compared to its average volume of 71,257. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $6.53 and a 12 month high of $9.14. The company has a market capitalization of $15.23 billion, a PE ratio of 15.29, a PEG ratio of 2.05 and a beta of 0.20. The firm's fifty day moving average is $8.68 and its 200 day moving average is $8.28. The company has a quick ratio of 6.13, a current ratio of 6.63 and a debt-to-equity ratio of 0.01.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.02. The firm had revenue of $672.90 million during the quarter, compared to the consensus estimate of $719.55 million. Analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current fiscal year.
About Shionogi & Co., Ltd. Unsponsored ADR
(
Get Free Report)
Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.
Featured Articles
Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list.
While Shionogi & Co., Ltd. Unsponsored ADR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.